Loading...
XNAS
TECH
Market cap8.26bUSD
Jul 08, Last price  
52.68USD
1D
2.21%
1Q
-2.57%
Jan 2017
104.92%
Name

Bio-Techne Corp

Chart & Performance

D1W1MN
P/E
49.13
P/S
7.13
EPS
1.07
Div Yield, %
0.46%
Shrs. gr., 5y
0.66%
Rev. gr., 5y
10.17%
Revenues
1.16b
+1.97%
178,652,000202,617,000223,482,000257,420,000263,956,000269,047,000289,962,000314,560,000310,575,000357,763,000452,246,000499,023,000563,003,000642,993,000714,006,000738,691,000931,032,0001,105,599,0001,136,702,0001,159,060,000
Net income
168m
-41.07%
66,132,00073,351,00085,111,000103,558,000105,242,000109,776,000112,302,000112,331,000112,561,000110,948,000107,735,000104,476,00077,286,000125,350,00096,072,000229,296,000140,410,000272,051,000285,263,000168,105,000
CFO
299m
+17.53%
74,433,00085,589,00090,503,000115,317,000111,321,000111,260,000127,194,000126,746,000123,562,000136,762,000139,359,000143,870,000143,448,000170,367,000181,619,000205,217,000352,164,000325,272,000254,393,000298,981,000
Dividend
Aug 19, 20240.08 USD/sh
Earnings
Aug 05, 2025

Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
IPO date
Feb 09, 1989
Employees
3,050
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
1,159,060
1.97%
1,136,702
2.81%
Cost of revenue
882,825
837,758
Unusual Expense (Income)
NOPBT
276,235
298,944
NOPBT Margin
23.83%
26.30%
Operating Taxes
17,584
53,217
Tax Rate
6.37%
17.80%
NOPAT
258,651
245,727
Net income
168,105
-41.07%
285,263
4.86%
Dividends
(50,419)
(50,285)
Dividend yield
0.44%
0.38%
Proceeds from repurchase of equity
(80,042)
(19,562)
BB yield
0.69%
0.15%
Debt
Debt current
25,840
22,398
Long-term debt
507,156
548,731
Deferred revenue
1,531
Other long-term liabilities
69,020
99,901
Net debt
127,983
455,801
Cash flow
Cash from operating activities
298,981
254,393
CAPEX
(62,877)
(38,244)
Cash from investing activities
(203,030)
(265,649)
Cash from financing activities
(122,398)
22,616
FCF
229,098
93,853
Balance
Cash
152,863
204,310
Long term investments
252,150
(88,982)
Excess cash
347,060
58,493
Stockholders' equity
1,248,513
1,244,973
Invested Capital
2,223,268
2,385,106
ROIC
11.23%
11.73%
ROCE
10.75%
11.80%
EV
Common stock shares outstanding
160,774
161,855
Price
71.65
-12.23%
81.63
-5.80%
Market cap
11,519,457
-12.81%
13,212,224
-7.10%
EV
11,647,440
13,668,025
EBITDA
387,946
406,182
EV/EBITDA
30.02
33.65
Interest
15,736
11,215
Interest/NOPBT
5.70%
3.75%